Clinical Laboratory Services Sector Outlook — September 2026
A sector outlook on Clinical Laboratory Services covering scaled lab networks, specialty diagnostics and adjacent models. It benchmarks 22 approved companies on EV/Revenue (CY2027E), reviews precedent transactions, and sets out strategic implications for owners, operators and boards assessing growth, reimbursement
Key figures
- 4.5x
- Sector median EV/Revenue (CY2027E) 18 rated companies
- 9.0x
- Faster-growth cohort multiple 9 companies above 15% growth
- 2.6x
- Slower-growth cohort multiple 8 companies below 15% growth
- 82%
- Forward revenue coverage 18 of 22 approved companies
Read the report
1 / 22 · HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES
Executive summary
Clinical Laboratory Services does not trade as one operating model. Faster-growing testing platforms carry a middle EV/Revenue multiple of 9.0x versus 2.6x for slower-growing names, and business model shifts the frame further, with specialty diagnostics at 3.6x against 8.1x for adjacent models. Forward revenue is the broadest available yardstick, covering 82% of the approved set, while precedent transactions split between revenue and earnings lenses by asset type.
Key findings
- Faster-growing testing platforms command a clear forward revenue premium.
- Business model, not just sector membership, drives valuation differences.
- Forward revenue is the broadest valuation yardstick, covering 82% of the set.
- Precedent deals split between revenue and earnings lenses by asset type.
What each page shows
The analyst’s walkthrough of the deck, page by page.
- 01
HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES
This is the cover page identifying the Clinical Laboratory Services sector outlook dated September 2026.
We open the Clinical Laboratory Services outlook with the segment breadcrumb and valuation basis that anchor everything that follows. The analysis is built on EV/Revenue (CY2027E) as of September 28, 2026, so every figure in the deck ties back to the same date and basis.
Everything on this page
HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › CLINICAL LABORATORY SERVICES Clinical Laboratory Services: Premiums Track Growth The report shows how growth, reimbursement durability and business model shape valuation across clinical laboratory services. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1
- 02CONTENTS
What This Report Covers
This page lists the report's five sections plus the appendix and confirms the bottom line comes first.
We lay out the five sections ahead — the bottom line, the landscape, valuation and situations, precedent transactions, and strategic implications — plus a full appendix. We put the bottom line first by design, so a reader who only has time for one section still leaves with the complete story. That structure lets you go as deep as you need, from headline conclusion to company-level detail.
Everything on this page
CONTENTS What This Report Covers 01 The Bottom Line Faster Growth Holds the Premium Across a Market with Distinct Laboratory Models 02 The Landscape Different Laboratory Models Compete for Capital on Different Terms 03 Valuation & Situations The Premium Sits with Faster-Growing Testing Platforms 04 Precedent Transactions Precedent Transactions Separate Growth Platforms from Scaled Laboratory Economics 05 Strategic Implications Reimbursement Quality and Scalable Growth Deserve Management Attention 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2
- 0301 · THE BOTTOM LINE
Clinical Laboratory Services Spans Scaled Lab Networks, Specialty Diagnostics and Adjacent Models
This page summarizes the sector's structure and the four headline conclusions on growth, model, valuation basis and precedent transactions.
We find that Clinical Laboratory Services spans scaled lab networks, specialty diagnostics and adjacent models, each priced on different terms. Names above 15% growth carry a middle multiple of 9.0x versus 2.6x below that threshold, and business model shifts the frame further — specialty diagnostics sit at 3.6x while adjacent models sit at 8.1x. Forward revenue is the practical common yardstick, with 82% of the approved set carrying an estimate, and precedent transactions split between revenue and earnings lenses depending on the asset. Together, these patterns show why growth and business model, not sector membership alone, should anchor how you read valuation here.
Everything on this page
01 · THE BOTTOM LINE Clinical Laboratory Services Spans Scaled Lab Networks, Specialty Diagnostics and Adjacent Models The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (18 of 22 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (20 of 22 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 The Premium Sits with Faster Growth Among 9 names above 15% growth, the middle forward revenue multiple is 9.0x. Among 8 names below that threshold, it is 2.6x. 2 Business Model Changes the Valuation Frame Specialty diagnostics and laboratory research services represent 73% of the set and sit at 3.6x. The 3 adjacent-model names sit at 8.1x, showing that workflow and revenue model matter alongside sector membership. 3 Forward Revenue Is the Practical Common Yardstick 18 of 22 approved companies have a forward revenue estimate, equal to 82% of the set. Meaningful forward EBITDA is available for 8 of 22, so revenue provides the broader comparison while still crediting forecast growth. 4 Transactions Use Different Lenses for Different Assets Of the 8 transactions with disclosed terms, 6 carry revenue multiples and 3 carry EBITDA multiples. The mix is consistent with buyers viewing growth testing platforms through revenue and scaled laboratory operations through network economics. 4.5x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 4 of 22 names are… 13.0x Premium end EV/Revenue vs 1.0x at the discount end top quartile (n=5) against bottom quartile (n=5) on EV/Revenue — the spread the report explains 8 Transactions with disclosed terms 43 recorded in this tier · 1 told as case studies, the full list in the appendix
- 04SECTION 02
02
This divider introduces the section on how different laboratory models compete for capital.
We turn next to how testing economics, reimbursement pathways and workflow ownership shape the way capital markets read each group. This section sets up the market map and landscape pages that follow.
Everything on this page
SECTION 02 02 THE LANDSCAPE Different Laboratory Models Compete for Capital on Different Terms Testing economics, reimbursement pathways and workflow ownership shape how the market reads each group. 02 of 06 Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4
- 0502 · MARKET MAP
Capital Separates Core Testing Platforms from Adjacent Revenue Models
This page groups the 22 approved companies by business segment and shows each group's median EV/Revenue (CY2027E).
We group the approved universe into business segments and plot each segment's median EV/Revenue (CY2027E) as of September 28, 2026. This separates core testing platforms from adjacent revenue models on the same valuation basis, using group medians on rated names only. The spread across groups shows that segment membership carries a distinct valuation signature, which is the starting point for the deeper cuts on the following pages.
Everything on this page
02 · MARKET MAP Capital Separates Core Testing Platforms from Adjacent Revenue Models 22 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 SPECIALTY DIAGNOSTICS AND LABORATORY RESEARCH SERVICES 16 cos median 3.6x Natera (NTRA) Quest Diagnostics (DGX) Labcorp Holdings (LH) Guardant Health (GH) BillionToOne (BLLN) GRAIL (GRAL) Veracyte (VCYT) CareDx (CDNA) NeoGenomics (NEO) GeneDx Holdings (WGS) Castle Biosciences (CSTL) Fulgent Genetics (FLGT) Exagen (XGN) MDxHealth S.A. (MDXH) Insight (IMDX) Sera Prognostics (SERA) This group anchors the sector through assay revenue, payer coverage and laboratory operating leverage. ADJACENT: THERAPEUTICS DEVELOPMENT 3 cos 12.7x · 1 rated Adaptive (ADPT) Aclaris (ACRS) YD Bio Limited (YDES) This group links testing capabilities with therapeutics development, creating a different evidence and funding profile. ADJACENT MODELS 3 cos median 8.1x Tempus AI (TEM) Prenetics Global (PRE) Lucid Diagnostics (LUCD) These businesses extend into data, consumer access and device-enabled collection, broadening the routes to revenue.
- 0602 · LANDSCAPE
The Sector Contains Three Models with Different Paths to Durable Revenue
This page describes the three business models in the sector and their paths to durable revenue.
We characterize the approved universe as three models with different paths to durable revenue, each summarized on the same EV/Revenue (CY2027E) basis. The what-they-do and why-it-matters framing is our view, built on the segment medians shown here and detailed further in the appendix. Understanding which model a name belongs to is a precondition for reading its multiple correctly.
Everything on this page
02 · LANDSCAPE The Sector Contains Three Models with Different Paths to Durable Revenue Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Specialty diagnostics and laboratory research services 16 73% 3.6x Natera, Inc. (NTRA) · Quest Diagnostics Incorporated (DGX) · +14 more Testing platforms anchor the sector. The group represents 73% of the set and sits at 3.6x. Value depends on reimbursed requisition growth, average realisation per test and the ability to scale accessions through the laboratory base. Adjacent: therapeutics development 3 14% 12.7x n=1 Adaptive Biotechnologies Corporation (ADPT) · Aclaris Therapeutics, Inc. (ACRS) · +1 more Therapeutics links reshape the story. The group connects laboratory capabilities with therapeutics development. Clinical evidence, partnership depth and the route from research activity to durable revenue become central to how the model is assessed. Adjacent models 3 14% 8.1x Tempus AI, Inc. (TEM) · Prenetics Global Limited (PRE) · +1 more New channels broaden the model. The 3 names sit at 8.1x and span data, consumer access and device-enabled collection. Their standing reflects different routes into ordering workflow, specimen capture and recurring demand.
- 07SECTION 03
03
This divider introduces the section on public market valuation and where the premium sits.
We move now into public market valuation, where the premium sits with faster-growing testing platforms even though the forward revenue range stays wide. The pages ahead unpack that spread and what sits behind it.
Everything on this page
SECTION 03 03 VALUATION & SITUATIONS The Premium Sits with Faster-Growing Testing Platforms The forward revenue range remains wide even after forecast growth is reflected. 03 of 06 Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7
- 0803 · PUBLIC MARKET VALUATION
The Top of the Valuation Range Sits with Expansion Platforms Carrying Durable Revenue
This page ranks all 18 rated companies on EV/Revenue (CY2027E) against a sector median of 4.5x.
We rank the 18 rated companies on EV/Revenue (CY2027E) and find a sector median of 4.5x, with the top of the range sitting with expansion platforms that carry durable revenue. We use EV/Revenue as the primary lens because practitioners price this growth set on revenue, and a meaningful share of the set is loss-making on forward EBITDA. Tier zones are our groupings cut at the rated set's quartiles, letting you see at a glance where a given name sits relative to peers. The ranking is the reference point for every valuation conversation later in this deck.
Everything on this page
03 · PUBLIC MARKET VALUATION The Top of the Valuation Range Sits with Expansion Platforms Carrying Durable Revenue EV / Revenue (CY2027E) · all 18 rated companies, sorted descending · sector median 4.5x · EV/Revenue is the lens because practitioners price this growth set on revenue and 4 of 22 names are loss-making on forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (18 of 22 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (20 of 22 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 13.0x CORE · median 4.5x DISCOUNT · median 1.0x Sector median 4.5x WHAT SEPARATES THE TWO ENDS The premium sits with growth. The premium end sits at 13.0x, alongside faster growth and testing models still expanding ordering breadth, coverage and menu reach. The discount reflects mature economics. The discount end sits at 1.0x and includes businesses where current scale or growth does not command the same forward revenue valuation. Forward valuation raises the bar. The lens already reflects forecast revenue. A premium that remains therefore signals market confidence in the durability of expansion, not simply the presence of a growth forecast.
- 0903 · VALUATION DRIVERS
Faster Growth Is Associated with a Clear Forward Revenue Premium
This page splits the rated set into growth and margin cohorts and compares their median EV/Revenue.
We split rated names into faster- and slower-growth cohorts, and separately into higher- and lower-margin cohorts, each cut at its own covered median. The faster-growth cohort carries a middle multiple of 9.0x against 2.6x for the slower cohort, a clear forward revenue premium associated with growth. These are cohort medians on rated names with the required estimates, and the association we observe here is directional, not causal. It tells you which lever — growth or margin — the market is rewarding more clearly today.
Everything on this page
03 · VALUATION DRIVERS Faster Growth Is Associated with a Clear Forward Revenue Premium Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=9; slower n=8; higher-margin n=6; lower-margin n=5). Driver readings are NeuraCap views on the supplied data — association, not causation. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 15% · EBITDA-margin split at 12% Growth Creates the Clearest Separation in the Set Among 9 names above 15% growth, the middle multiple is 9.0x, compared with 2.6x among 8 names below the threshold. Revenue Quality Determines Whether Expansion Can Endure Payer mix, in-network contracting, denial experience and average realisation per test shape whether requisition growth converts into durable collected revenue. The Premium Sits Alongside Ordering and Coverage Expansion The market distinction is consistent with broader ordering depth, reimbursement progress and menu pull-through carrying more weight than current profitability alone.
- 1003 · SITUATION MAP
Valuation Against Growth Shows Which Names Are Priced Ahead of Their Growth and Which Sit Behind It
This page maps rated names on valuation versus growth relative to the sector medians to characterize situations.
We plot valuation against growth, cutting on EV/Revenue versus the 4.5x sector median and on revenue growth versus the 15% covered median. This produces a map of which names are priced ahead of their growth and which sit behind it, using the cohort's own medians as boundaries. The page characterizes situations only — it is not a recommendation to buy or sell any security. It is a starting point for asking why a given name sits where it does.
Everything on this page
03 · SITUATION MAP Valuation Against Growth Shows Which Names Are Priced Ahead of Their Growth and Which Sit Behind It Cut on EV / Revenue vs the sector median (4.5x) (rows) and revenue growth vs the covered median (15%) (columns) · 1 rated names without the second measure are not mapped · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium Growth Platforms Above-median multiple · above-median revenue growth 6 names Natera, Inc. (NTRA) · Guardant Health, Inc. (GH) · Tempus AI, Inc. (TEM) · +3 more These 6 names pair above-middle growth with above-middle valuation. The operating task is to defend reimbursement durability, ordering breadth and laboratory execution as scale builds. Premium but Slower Growth Above-median multiple · below-median revenue growth 2 names Veracyte, Inc. (VCYT) · CareDx, Inc (CDNA) These 2 names retain above-middle valuation despite slower growth. The question is whether payer coverage, menu expansion or deeper ordering can restore momentum without weakening revenue quality. Growth Awaiting Recognition Below-median multiple · above-median revenue growth 3 names GeneDx Holdings Corp. (WGS) · Fulgent Genetics, Inc. (FLGT) · Prenetics Global Limited (PRE) These 3 names show above-middle growth but remain below the middle of the valuation range. The gap points management toward realisation, payer mix, retention and the cost required to support expansion. Repositioning Required Below-median multiple · below-median revenue growth 6 names Quest Diagnostics Incorporated (DGX) · Labcorp Holdings Inc. (LH) · NeoGenomics, Inc. (NEO) · +3 more These 6 names sit below the middle on both growth and valuation. The agenda centres on menu focus, network efficiency and a clearer path from accessions to collected revenue.
- 1103 · GROWTH VS PROFITABILITY
Few Names Combine Growth and Margin, While Growth-Only Names Hold Higher Valuations
This page plots companies on growth versus margin and shows median EV/Revenue per quadrant.
We plot the companies with both growth and margin estimates on a two-by-two grid cut at the covered medians of 15% growth and 12% margin. Few names combine growth and margin, while growth-only names hold higher valuations than the other quadrants. The quadrant medians are drawn from a small covered set, so read them as directional signals rather than precise benchmarks. This framing helps you see where a name's valuation is coming from — growth, margin, both, or neither.
Everything on this page
03 · GROWTH VS PROFITABILITY Few Names Combine Growth and Margin, While Growth-Only Names Hold Higher Valuations Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 11 companies with both estimates · cuts at the covered medians (11% growth, 12% margin) · median EV/Revenue per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/Revenue (balanced n=3; margin-only n=3; growth-only n=3; neither n=2). Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 10% 20% 30% 0% 10% 20% MARGIN ONLY median 2.6x BALANCED median 9.0x NEITHER median 2.6x GROWTH ONLY median 13.0x DGX LH CDNA NEO CSTL VCYT NTRA ADPT TEM BLLN GH x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS The map uses 11% margin and 12% growth as its dividing lines. Three names clear both bars, three clear margin alone, three clear growth alone and two clear neither. Veracyte, Inc. (VCYT), Adaptive Biotechnologies Corporation (ADPT) and BillionToOne, Inc. (BLLN) occupy the balanced group. The pattern shows that margin alone offers limited valuation separation in this sample. The margin-only median rests on 3 names and is lifted by CDNA at 6.0x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 1 of 11 names clear it (BLLN).
- 1203 · THE AGENDA
Buyers Price These Paths Differently; Where to Concentrate Operating Investment Stays a Management Call
This page frames the questions an owner or acquirer should resolve, given how buyers price each path differently.
We frame this page as the questions an owner or acquirer should resolve, since buyers clearly price these paths differently even as where to concentrate operating investment stays a management call. This is our advisory judgment grounded in the cohort data shown earlier, not investment advice. The agenda gives you a structured way to prioritize among growth, margin and model choices rather than treating them as equally urgent.
Everything on this page
03 · THE AGENDA Buyers Price These Paths Differently; Where to Concentrate Operating Investment Stays a Management Call NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Deepen Reimbursement Durability Prioritise in-network contracting, denial reduction and payer mix where stronger collection can improve the quality of requisition growth. What changes the answer: Coverage decisions, cash collection and average realisation per test show sustained improvement. Build or Acquire Network Density Compare internal investment with combinations that add specimen volume, laboratory capacity or billing infrastructure. The transaction record shows revenue and earnings lenses alongside different operating models. What changes the answer: Incremental accessions can move through the network with attractive cost per accession. Shift the Menu Toward Differentiated Testing Concentrate commercial and evidence spending on assays with clearer coverage pathways, stronger clinician pull-through and less exposure to routine-menu pricing pressure. What changes the answer: Ordering breadth and collected revenue improve faster than the supporting cost base. Develop the Data Revenue Stream Assess whether clinico-genomic data and biopharma partnerships can add a durable revenue stream alongside clinical testing without distracting from reimbursement execution. What changes the answer: Partnership demand becomes repeatable and supports attractive revenue quality.
- 13SECTION 04
04
This divider introduces the section on precedent transactions.
We turn to precedent transactions next, where growth platforms and scaled laboratory economics are benchmarked side by side on both revenue and earnings measures. The case studies and full list that follow show how the lens buyers use shifts with the target's operating model.
Everything on this page
SECTION 04 04 PRECEDENT TRANSACTIONS Precedent Transactions Separate Growth Platforms from Scaled Laboratory Economics Revenue and earnings benchmarks appear side by side across the transaction record. 04 of 06 Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13
- 1404 · DEAL CASE STUDIES
Transaction Benchmarks Shift with the Target's Operating Model
This page walks through case studies from the transactions with disclosed terms, using multiples on LTM financials at announcement.
We walk through case studies drawn from the transactions with disclosed terms, using multiples on LTM financials at announcement where disclosed. Transaction benchmarks shift with the target's operating model, and deal multiples are not directly comparable to the CY2027E public basis, so we do not claim a spread between the two. The why-the-deal-happened read is our interpretation of the recorded evidence. These cases give you a grounded reference for how buyers have actually priced comparable assets.
Everything on this page
04 · DEAL CASE STUDIES Transaction Benchmarks Shift with the Target's Operating Model 1 of 8 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 28 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 35 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 May-2022 $1.2B Artisan Acquisition Corp. Artisan Acquisition Corp. paired with Prenetics Group Limited in a completed growth-testing transaction. EV / LTM revenue 4.0x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The combination suggests interest in Prenetics Group Limited's testing platform and its route to broader demand. The strategic fit joins a transaction vehicle with a growth-oriented diagnostics business. HOW THE TARGET WAS VALUED The disclosed value was $1.2B at 4.0x revenue. That benchmark sits above mature laboratory references and below the premium end of the public set.
- 15SECTION 05
05
This divider introduces the section on strategic implications for management.
We close the analysis with strategic implications, where reimbursement quality and scalable growth deserve management attention. The practical agenda ahead covers revenue durability, menu economics and network efficiency.
Everything on this page
SECTION 05 05 STRATEGIC IMPLICATIONS Reimbursement Quality and Scalable Growth Deserve Management Attention The practical agenda is to improve revenue durability, menu economics and network efficiency. 05 of 06 Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15
- 1605 · STRATEGIC IMPLICATIONS
The Strategic Agenda Is Durable Growth, Disciplined Mix and Scalable Laboratory Economics
This page sets out the strategic agenda around durable growth, disciplined mix and scalable laboratory economics.
We set the strategic agenda around durable growth, disciplined mix and scalable laboratory economics, framed as the questions this data puts on the table for the next twelve months. This is our directional view, drawn from the analysis in this report, and it is offered as observation rather than recommendation. It gives owners, operators and boards a shared vocabulary for prioritizing where to focus over the coming year.
Everything on this page
05 · STRATEGIC IMPLICATIONS The Strategic Agenda Is Durable Growth, Disciplined Mix and Scalable Laboratory Economics NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Define Which Model Should Command Attention Choose whether the business is building a premium specialty testing platform, a scaled laboratory network or an adjacent model. Capital allocation should reinforce that position rather than blur it. FOR OPERATORS Convert Requisitions into Collected Revenue Manage payer mix, prior authorisation, denials and average realisation per test as tightly as accession growth. Volume without durable collection offers a weaker foundation for value. FOR BOARDS Test Growth Against Reimbursement Durability Evaluate evidence spending, menu expansion and network investment against visible progress in coverage, ordering depth and gross margin per test.
- 17SECTION 06
06
This divider introduces the appendix covering the full universe, methodology and sources.
We close with the full universe, methodology and sources behind every figure in the body. This appendix lets you trace any number back to its basis and underlying disclosure.
Everything on this page
SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17
- 1806 · PUBLIC COMPARABLES (1 OF 2)
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier
This page lists public comparables grouped by valuation tier, covering the first half of the rated set.
We list the public comparables here grouped by valuation tier, shading each name above or below the 4.5x sector median. Eighteen companies are rated on this basis, with four not rated for lack of an eligible EV/Revenue estimate. Tickers link back to the underlying source, so you can verify any individual name's figures directly. This is the detail behind every ranking and cohort shown earlier in the deck.
Everything on this page
06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (4.5x); amber marks below · 18 rated companies; 4 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 18 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥10.0x · median 13.0x · 5 companies GRAIL, Inc. GRAL Specialty diagnostics and laboratory research services $4.7B 20.7x 25% n/a n/a Natera, Inc. NTRA Specialty diagnostics and laboratory research services $57.9B 16.6x 20% 2% 22 Guardant Health, Inc. GH Specialty diagnostics and laboratory research services $23.9B 13.0x 35% 0% 36 Adaptive Biotechnologies Corporation ADPT Adjacent: therapeutics development $4.6B 12.7x 22% 12% 35 Lucid Diagnostics Inc. LUCD Device-enabled specimen collection with lab-run testing $173M 10.3x n/a n/a n/a CORE — 2.2x–10.0x · median 4.5x · 8 companies BillionToOne, Inc. BLLN Specialty diagnostics and laboratory research services $5.2B 9.0x 26% 18% 44 Tempus AI, Inc. TEM Diagnostic data and laboratory informatics platforms $16.0B 8.1x 23% 8% 32 CareDx, Inc CDNA Specialty diagnostics and laboratory research services $3.1B 6.0x 6% 14% 20 Veracyte, Inc. VCYT Specialty diagnostics and laboratory research services $3.2B 4.9x 11% 28% 39 GeneDx Holdings Corp. WGS Specialty diagnostics and laboratory research services $2.5B 4.1x 24% n/a n/a NeoGenomics, Inc. NEO Specialty diagnostics and laboratory research services $2.8B 3.1x 10% 10% 20 Quest Diagnostics Incorporated DGX Specialty diagnostics and laboratory research services $32.7B 2.6x 5% 20% 25 Exagen Inc. XGN Specialty diagnostics and laboratory research services $210M 2.6x 10% n/a n/a DISCOUNT — <2.2x · median 1.0x · 5 companies Castle Biosciences, Inc. CSTL Specialty diagnostics and laboratory research services $864M 2.1x 10% 5% 16
- 1906 · PUBLIC COMPARABLES (2 OF 2)
Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier
This page continues the public comparables list grouped by valuation tier for the remaining rated names.
We continue the comparables list here, completing the rated set of 18 companies shaded above or below the 4.5x sector median. The same sourcing and linking convention applies, so every row traces back to its underlying disclosure. Together with the prior page, this gives you the complete rated universe behind the deck's valuation conclusions.
Everything on this page
06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (4.5x); amber marks below · 18 rated companies; 4 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 18 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 DISCOUNT — CONTINUED — <2.2x · median 1.0x · 5 companies Labcorp Holdings Inc. LH Specialty diagnostics and laboratory research services $31.8B 2.1x 5% 18% 23 Fulgent Genetics, Inc. FLGT Specialty diagnostics and laboratory research services $372M 1.0x 15% n/a n/a Prenetics Global Limited PRE Adjacent: consumer self-collection health products $278M 0.7x 82% n/a n/a MDxHealth S.A. MDXH Specialty diagnostics and laboratory research services $78M 0.6x 15% n/a n/a
- 2006 · PRECEDENT TRANSACTIONS (1 OF 1)
All Precedent Transactions with Disclosed Terms, Newest First
This page lists all transactions with disclosed terms, newest first, with multiples on LTM financials at announcement.
We list every transaction with disclosed terms here, newest first, with multiples on LTM financials at announcement where disclosed. Deal values link back to the underlying filing, and we note that these deal multiples are not directly comparable to the CY2027E public basis used elsewhere in this deck. A number of recorded transactions carry data-quality flags and are shown as recorded in the filing rather than adjusted. This is the complete transaction record behind the case studies discussed earlier.
Everything on this page
06 · PRECEDENT TRANSACTIONS (1 OF 1) All Precedent Transactions with Disclosed Terms, Newest First 8 transactions with disclosed terms in this tier (43 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 28 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate precedent id); figures are shown as recorded in the filing. 35 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters May-2025 PAI Partners SAS & British Columbia Investment Management Corporation → Spectra Laboratories (U.S. laboratory testing services) and Malaysia clinic operations n/a n/a 8.5x PAI Partners SAS & British Columbia Investment Management Corporation agreed to acquire Spectra Laboratories (U.S. laboratory testing services) and Malaysia clinic operations at 8.5x EBITDA. The benchmark aligns with a scaled testing and clinic platform. Apr-2023 Mars, Incorporated → Heska Corporation n/a n/a 8.8x Mars, Incorporated's terminated transaction for Heska Corporation was recorded at 8.8x EBITDA. The multiple offers an earnings reference for an established diagnostics business. May-2022 Artisan Acquisition Corp. → Prenetics Group Limited $1.2B 4.0x n/a Artisan Acquisition Corp.'s completed transaction with Prenetics Group Limited was recorded at $1.2B and 4.0x revenue. The valuation sits alongside a testing platform positioned for expansion. Sep-2019 Advent International → Razor Genomics, Inc. n/a 2.4x 22.4x Advent International's announced transaction for Razor Genomics, Inc. was recorded at 2.4x revenue and 22.4x EBITDA. The two measures show how growth and established earnings can both inform a specialty diagnostics benchmark. May-2011 Werfen Life → Accriva Diagnostics n/a 4.0x n/a Werfen Life's announced transaction for Accriva Diagnostics used a revenue multiple. The record provides a benchmark for diagnostics content without relying on current earnings. n/a n/a → Labcorp Holdings Inc. n/a 1.8x n/a Labcorp Holdings Inc. was recorded at 1.8x revenue. The benchmark is consistent with a scaled laboratory platform being assessed differently from a growth molecular testing business. n/a n/a → Tempus AI, Inc. n/a 8.1x n/a Tempus AI, Inc. was recorded using a revenue multiple. The transaction record places a data-led laboratory model above mature reference-lab benchmarks. n/a Quidel Corporation → ICL Diagnostics Holdings plc n/a 3.8x n/a Quidel Corporation's announced transaction for ICL Diagnostics Holdings plc was recorded at 3.8x revenue. The benchmark sits between scaled laboratory and higher-growth testing references.
- 2106 · METHODOLOGY
Sources, Assumptions and Data Quality
Sources, Assumptions and Data Quality.
Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. 21
Everything on this page
06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice 21 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (18 of 22 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (20 of 22 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Clinical Laboratory Services and it clears the coverage gate with 18 of 22 companies (82%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (8 of 22 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 88 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 838 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (837) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.
- 22
The Premium Sits with Durable Growth, Broad Reimbursement and Scalable Testing Economics.
This is the closing page restating that the premium sits with durable growth, broad reimbursement and scalable testing economics.
We end where we began: the premium in this sector sits with durable growth, broad reimbursement and scalable testing economics. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure you want to trace further.
Everything on this page
The Premium Sits with Durable Growth, Broad Reimbursement and Scalable Testing Economics. NeuraCap AI — Clinical Laboratory Services Coverage September 2026 · Prepared by NeuraCap AI · Confidential Clinical Laboratory Services Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 22
Sources and methodology
This report covers Clinical Laboratory Services (Health Care › Health Care Equipment and Services › Clinical Laboratory Services) with market data and consensus estimates as of September 28, 2026. The company universe is the 22 listed companies whose core business is Clinical Laboratory Services according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Aclaris Therapeutics, Inc. (ACRS), Adaptive Biotechnologies Corporation (ADPT), BillionToOne, Inc. (BLLN), CareDx, Inc (CDNA), Castle Biosciences, Inc. (CSTL), Quest Diagnostics Incorporated (DGX), Fulgent Genetics, Inc. (FLGT), Guardant Health, Inc. (GH), GRAIL, Inc. (GRAL), Insight Molecular Diagnostics Inc. (IMDX), Labcorp Holdings Inc. (LH), Lucid Diagnostics Inc. (LUCD), MDxHealth S.A. (MDXH), NeoGenomics, Inc. (NEO), Natera, Inc. (NTRA), Prenetics Global Limited (PRE), Sera Prognostics, Inc. (SERA), Tempus AI, Inc. (TEM), Veracyte, Inc. (VCYT), GeneDx Holdings Corp. (WGS), Exagen Inc. (XGN), YD Bio Limited Ordinary Shares (YDES). The market map groups them by business vertical — Specialty diagnostics and laboratory research services: 16 companies (NTRA, DGX, LH, GH, BLLN, GRAL, VCYT, CDNA, NEO, WGS, CSTL, FLGT, XGN, MDXH, IMDX, SERA); Adjacent: therapeutics development: 3 companies (ADPT, ACRS, YDES); Adjacent models: 3 companies (TEM, PRE, LUCD). 18 of the 22 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
Scope and company universe
This report covers Clinical Laboratory Services (Health Care › Health Care Equipment and Services › Clinical Laboratory Services) with market data and consensus estimates as of September 28, 2026. The company universe is the 22 listed companies whose core business is Clinical Laboratory Services according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Aclaris Therapeutics, Inc. (ACRS), Adaptive Biotechnologies Corporation (ADPT), BillionToOne, Inc. (BLLN), CareDx, Inc (CDNA), Castle Biosciences, Inc. (CSTL), Quest Diagnostics Incorporated (DGX), Fulgent Genetics, Inc. (FLGT), Guardant Health, Inc. (GH), GRAIL, Inc. (GRAL), Insight Molecular Diagnostics Inc. (IMDX), Labcorp Holdings Inc. (LH), Lucid Diagnostics Inc. (LUCD), MDxHealth S.A. (MDXH), NeoGenomics, Inc. (NEO), Natera, Inc. (NTRA), Prenetics Global Limited (PRE), Sera Prognostics, Inc. (SERA), Tempus AI, Inc. (TEM), Veracyte, Inc. (VCYT), GeneDx Holdings Corp. (WGS), Exagen Inc. (XGN), YD Bio Limited Ordinary Shares (YDES). The market map groups them by business vertical — Specialty diagnostics and laboratory research services: 16 companies (NTRA, DGX, LH, GH, BLLN, GRAL, VCYT, CDNA, NEO, WGS, CSTL, FLGT, XGN, MDXH, IMDX, SERA); Adjacent: therapeutics development: 3 companies (ADPT, ACRS, YDES); Adjacent models: 3 companies (TEM, PRE, LUCD). 18 of the 22 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.
What was excluded and why
88 records failed a validation gate and never feed a statistic in this report (80 excluded from aggregate; 8 quarantined). Each exclusion, with its reason: ACRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ACRS — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADPT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADPT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADPT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ADPT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CDNA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CDNA — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CSTL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CSTL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CSTL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CSTL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FLGT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FLGT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FLGT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · FLGT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FLGT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · FLGT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GH — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · GH — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · GH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · GH — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.
Primary valuation basis and how it was chosen
Primary valuation basis: EV / Revenue on CY2027E consensus (18 of 22 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (20 of 22 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Clinical Laboratory Services and it clears the coverage gate with 18 of 22 companies (82%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (8 of 22 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 11 of 22 companies; EV / rEVenue: 19 of 22 companies; P/E: 8 of 22 companies. 4 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 13 companies show a non-meaningful P / E denominator and are excluded from that statistic.
How the multiples and statistics are computed
Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥10.0x, Core 2.2x–10.0x, Discount <2.2x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 4.5x = median(ev_revenue CY2027E) (18 rated companies) · 13.0x = median(ev_revenue CY2027E) within Premium tier (n=5) · 4.5x = median(ev_revenue CY2027E) within Core tier (n=8) · 1.0x = median(ev_revenue CY2027E) within Discount tier (n=5) · 9.0x = median(ev_revenue CY2027E) | growth ≥ 15% (n=9) · 2.6x = median(ev_revenue CY2027E) | growth < 15% (n=8) · 5.4x = median(ev_revenue CY2027E) | EBITDA margin ≥ 12% (n=6) · 8.1x = median(ev_revenue CY2027E) | EBITDA margin < 12% (n=5) · 24% = median Rule of 40 score (revenue growth + EBITDA margin) (n=11) · 9.0x = median(ev_revenue CY2027E) within balanced quadrant (n=3) · 2.6x = median(ev_revenue CY2027E) within marginOnly quadrant (n=3) · 13.0x = median(ev_revenue CY2027E) within growthOnly quadrant (n=3) · 2.6x = median(ev_revenue CY2027E) within neither quadrant (n=2) · 6.0x = ev_revenue CY2027E for CDNA (quadrant outlier)
Precedent transactions: what is in the record and why
The precedent record holds the M&A transactions in Clinical Laboratory Services recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 43 transactions were recorded for this industry; 8 are shown. 35 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 15 × deal value unit unresolved; 9 × no evidence record; 1 × duplicate precedent id; 2 × divestiture roles reassigned; 1 × financial target ev not meaningful. Case studies lead with the 1 richest stories — disclosed value, a readable multiple, newest first.
Sources
Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 842 source documents stand behind this report; by publisher domain: sec.gov, home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.
Interpretation and important notice
Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.
This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.
More coverage in Health Care
- Bi-Weekly Update · Sep 28, 2026Clinical Laboratory Services Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
- Bi-Weekly Update · Sep 28, 2026Medical Devices Bi-Weekly Industry Events & M&A Update — September 14–28, 2026
- Sector Report · Sep 28, 2026Medical Devices Sector Outlook — September 2026
- Sector Report · Sep 28, 2026Managed Health Care Sector Outlook — September 2026
Want this analysis for a company in Clinical Laboratory Services?
Company valuation reports run the same method against a single business — public or private.